Physician Awareness of the Safe Use of Cyproterone Acetate in Europe: A Survey on the Effectiveness of Additional Risk Minimization Measures

The study aimed to assess European physicians' awareness of the updated safety information regarding the use of Cyproterone acetate (CPA) monotherapy, specifically the risk of meningioma with increased cumulative doses. A web-based survey was conducted with 613 physicians across five European countries who had prescribed CPA in the past year. The results showed that 85% of physicians were aware that CPA should be prescribed at the lowest effective dose, 75% knew about the increased risk of meningioma with higher cumulative doses, and 73% understood that CPA treatment must cease if a patient is diagnosed with meningioma. However, only 40% recalled receiving the Direct Healthcare Professional Communication (DHPC), and 42% recalled receiving the revised summary of product characteristics (SmPC). Despite the low recall of these communications, the majority of physicians were informed about the risks and necessary precautions when prescribing CPA.